S1475 Burden and Impact of Fatigue on Patients with Crohn’s Disease and Ulcerative Colitis in the United States and Europe: Results from the Communicating Needs and Features of IBD Experiences (CONFIDE) Survey
Bibliographic record
Abstract
Introduction: Fatigue is a common yet debilitating symptom with multifactorial etiology (e.g., inflammation, sleep disturbances) which significantly impacts quality of life of patients (pts) with inflammatory bowel disease (IBD). The Communicating Needs and Features of IBD Experiences (CONFIDE) study explored the burden and impact of Crohn’s disease/ulcerative colitis (CD/UC)-related symptoms on pts’ lives in the United States (US), Europe (EU5: France, Germany, Italy, Spain, and UK) and Japan. Methods: An online, quantitative, cross-sectional survey was conducted in pts with moderate-to-severe CD/UC. Moderate-to-severe CD/UC were defined using criteria based on previous treatment, steroid use, and/or hospitalization. Patients were asked about the impact of CD/UC-related fatigue on their work/school, social, physical, and sexual activities. Descriptive statistics were used to summarize data from US and EU5. Results: Overall, 215 US (men [M]=55%, mean age=41 years) and 547 EU5 (M=55%, mean age=38 years) pts with CD, and 200 US (M=62%, mean age=40 years) and 556 EU5 (M=57%, mean age=39 years) pts with UC completed the survey (Table 1). Overall, 36% US and 34% EU5 pts with CD, and 28% US and 21% EU5 pts with UC reported currently experiencing fatigue (in the past month). A total of 46% US and 45% EU5 pts with CD, and 40% US and 31% EU5 pts with UC reported ever experiencing fatigue. Similar results were observed in pts receiving advanced therapies (Current: CD, US: 36%, EU5: 34%; UC, US: 26%, EU5: 20%; Ever: CD, US: 47%, EU5: 46%; UC, US: 36%, EU5: 29%). In past 3 months, 19–24% and 15–24% pts with CD and UC, respectively reported declining participation in work/school, social activities, and sports/physical exercise due to fatigue (Figure 1A). Among pts with CD/UC who ever experienced fatigue, most reported that fatigue impacted their work/school-related activities (CD, US:74%, EU5:71%; UC, US:70%, EU5:74%). Of these, >40% pts worked for fewer hours and >30% stopped working for the day sooner than planned due to CD/UC-related fatigue (Figure 1B). Among pts who reported reduced sexual activity in past 3 months (CD, US:69%, EU5:56%; UC, US:63%, EU5:53%), 38% US and 30% EU5 pts with CD, and 29% US and 18% EU5 pts with UC attributed it to CD/UC-related fatigue. Conclusion: Fatigue is a prevalent symptom of moderate-to-severe CD/UC which adversely affects pts’ work/school, social, physical, and sexual activities. This underscores the need to develop fatigue-related treatment strategies in CD and UC.Figure 1.: Impact of fatigue on health-related quality of life of patients with CD/UC (A) Patients who declined participation in work/school, social activities, and sports/physical exercise in the past 3 months due to CD/UC-related fatigue (B) Impact of CD/UC-related fatigue on work/school among patients who reported ever experiencing fatigue. CD, Crohn's disease; UC, Ulcerative colitis; US, United States. Table 1. - Demographics and characteristics of patients with CD and UC Patients with CD Patients with UC US (N=215) Europe (N=547) US (N=200) Europe (N=556) Mean age, years (SD) 40.9 (11.4) 38.0 (9.7) 40.4 (10.8) 38.9 (8.8) Male, n (%) 118 (54.9) 303 (55.4) 123 (61.5) 319 (57.4) Ethnicity, n (%) White 175 (81.4) 515 (94.1) 155 (77.5) 518 (93.2) Hispanic/Latino 21 (9.8) 1 (0.2) 23 (11.5) 3 (0.5) African American 12 (5.6) 0 18 (9.0) 0 Other* 6 (2.8) 31 (5.7) 4 (2.0) 35 (6.3) Time since diagnosis of CD/UC, (mean years [SD]) 8.7 (8.6) 9.2 (8.5) 7.9 (8.6) 7.9 (7.5) Advanced therapy, n (%)^ 125 (58.1) 347 (63.4) 153 (76.5) 301 (54.1) *Other races included Asian-Indian subcontinent, Asian-other, Japanese, Korean, Middle Eastern, Afro-Caribbean, Native American, Mixed race, South-East Asian, and other. ^Advanced therapy defined as biologic therapy, biosimilar, or Janus kinase inhibitor. CD, Crohn’s disease; SD, standard deviation; UC, ulcerative colitis; US, United States.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.004 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.000 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".